Broader Formulary Coverage Linked to Lower Odds of MS Relapse

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on Aug 8, 2025.

via HealthDay

FRIDAY, Aug. 8, 2025 -- Broader formulary coverage is associated with lower odds of multiple sclerosis (MS) relapse among Medicare beneficiaries, according to a study published online Aug. 1 in JAMA Network Open.

Barbara Blaylock, Ph.D., from Blaylock Health Economics LLC in Reno, Nevada, and colleagues examined the association between the breadth of formulary coverage for MS disease-modifying therapies and MS relapse in a retrospective cohort study that analyzed 100 percent Medicare administrative data from 2018 to 2022. Beneficiaries with stand-alone prescription drug plans (PDPs) and Medicare Advantage Prescription Drug plans (MA-PDs) were followed for at least five quarters (baseline: quarters 1 to 4; follow-up: quarter 5).

A total of 50,162 unique beneficiaries in PDPs and 34,708 in MA-PDs were included in the claims analysis. The researchers found that the MS relapse rate was greater for low- versus high-coverage PDPs and MA-PDs (odds ratios, 0.88 and 0.88). There was an association for broader formulary coverage during baseline with less MS relapse during follow-up in multivariable analyses (adjusted odds ratios, 0.93 and 0.94 for drugs and classes for PDP; 0.88 and 0.92 for drugs and classes for MA-PD, respectively).

"Patients with MS may need to try multiple drugs to find what works best for them. Broad formulary exclusions ultimately undermine the individualized care these patients need," lead author Geoffrey Joyce, Ph.D., from the University of Southern California, Los Angeles, said in a statement.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-08-09 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords